Source briefing
Pascal Geldsetzer on the Link Between the Shingles Vaccine and Dementia
Pascal Geldsetzer, MD, PhD, Assistant Professor of Medicine in Primary Care and Population Health at Stanford, joins The Future of Medicine to discuss a striking line of research: evidence that shingles vaccination may reduce the risk of dementia.Geldsetzer…
Read →
Source briefing
Statement on missing ICIJ journalist Micah Reddy
ICIJ lost contact with our colleague Micah Reddy, ICIJ's Africa coordinator, and local journalist Mohamed Willo Ismael ("Kooki Mahmoud"), in Djibouti City on Saturday, Sept. 19.
Read →
Source briefing
Living with a rare disease: Why lived experience must shape research
by Gemma Whyatt, Jodi Whitehouse Rare diseases are often defined by numbers and clinical perspectives, a narrative that needs re-writing. Drawing on decades of patient advocacy, two women living with the rare condition Congenital Melanocytic Naevus argue that…
Read →Source briefing
Chatbot attachment issues
When AI companions get a personality update, some users respond with grief, study finds
Read →Source briefing
Human medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: Opinion
Human medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: Opinion
Read →Source briefing
Human medicines European public assessment report (EPAR): Zeydovio, glepaglutide, Status: Opinion
Human medicines European public assessment report (EPAR): Zeydovio, glepaglutide, Status: Opinion
Read →Source briefing
Human medicines European public assessment report (EPAR): Sepalna, senaparib, Status: Opinion
Human medicines European public assessment report (EPAR): Sepalna, senaparib, Status: Opinion
Read →Source briefing
Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised
Human medicines European public assessment report (EPAR): Steqeyma, ustekinumab, Date of authorisation: 22/08/2024, Revision: 10, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 29, Status: Authorised
Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 29, Status: Authorised
Read →Source briefing
Programme of the 2026 annual meeting of the European network of paediatric research at EMA (EnprEMA)
Programme of the 2026 annual meeting of the European network of paediatric research at EMA (EnprEMA)
Read →